Ultra-Sensitive Cancer Screening in 24 Hours

ExoDiscovery Detect analyzes RNA biomarkers within exosomes, achieving 10,000x greater sensitivity than conventional methods. It detects cancer signals that others miss—with 97% accuracy¹. For pancreatic cancer, the test detects mutations including KRAS G12C, G12D, G12R, and G12V, which account for 96% of pancreatic cancer cases².

While traditional cancer tests require weeks of waiting, ExoDiscovery Detect delivers complete results in just 24 hours. This dramatic reduction in waiting time decreases patient anxiety and enables faster clinical decision-making when time matters most.

ExoDiscovery Detect requires only a standard blood draw with minimal sample volume (20μL plasma), reducing the need for costly, high-risk invasive procedures. Our technology seamlessly integrates with existing clinical workflows, making implementation simple for healthcare providers.